CoChat

A 24-Week Randomized, Double-Blind, Placebo-Controlled Study of Escitalopram for the Prevention of Generalized Social Anxiety Disorder

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: Escitalopram has proven efficacy in the short-term treatment of generalized social anxiety disorder (SAD). The present relapse prevention study investigated relapse rates during a 24-week, randomized, double-blind, placebo-controlled period in patients with generalized SAD who had responded to 12-week open-label treatment with escitalopram. METHOD: A total of 517 patients with a primary diagnosis of generalized SAD (per DSM-IV criteria) and a Liebowitz Social Anxiety Scale (LSAS) total score of > or = 70 received 12 weeks of open-label treatment with flexible doses (10-20 mg/day) of escitalopram. Of these patients, 371 responded (Clinical Global Impressions-Improvement scale [CGI-I] score of 1 or 2) and were randomly assigned to 24 weeks of double-blind treatment with escitalo-pram (10 or 20 mg/day) (N = 190) or placebo (N = 181), continuing with the dose level administered at the end of the open-label period. Relapse was defined as either an increase in LSAS total score of > or = 10 or withdrawal due to lack of efficacy, as judged by the investigator. The study was conducted from January 2001 to June 2002. RESULTS: Survival analysis of relapse and time to relapse showed a significant advantage for escitalopram compared to placebo (log-rank test: p < .001). The risk of relapse was 2.8 times higher for placebo-treated patients than for escitalopram-treated patients (p < .001), resulting in significantly fewer escitalopram-treated patients relapsing (22% vs. 50%), at both doses. Escitalopram was well tolerated during double-blind treatment of generalized SAD, and only 2.6% of the escitalopram-treated patients withdrew because of adverse events. The overall discontinuation rate, excluding relapses, was 13.2% for patients treated with escitalopram and 8.3% for patients treated with placebo. CONCLUSION: Escitalopram was effective and well tolerated in the long-term treatment of generalized SAD.

Overview

Integrity signals

Registry

Crossref · 10.4088/jcp.v66n1009

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 30 references

Cited by

See all 116

Metadata

Authors
Montgomery, S. A., Nil, R., Dürr-Pal, N., Loft, H., & Boulenger, J.-P.
Affiliations
Imperial College London (GB)
Venue
The Journal of Clinical Psychiatry
Published
2005-10-15
Volume
66
Issue
10
Pages
1270-1278
ISSN
0160-6689 (ISSN-L)
OpenAlex
W2045208941
Cited by
115
References
30
Citations by year
2026: 1 · 2025: 2 · 2024: 7 · 2023: 3 · 2022: 4 · 2021: 6 · 2019: 5 · 2018: 4 · 2017: 4 · 2016: 5 · 2015: 4 · 2014: 4 · 2013: 1 · 2012: 5
FWCI
14.22
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords
escitalopram, generalized social anxiety disorder, relapse prevention, long-term maintenance therapy, selective serotonin reuptake inhibitors, treatment response, drug tolerability, time to relapse
MeSH terms
Adolescent, Adult, Aged, Double-Blind Method, Drug Administration Schedule, Female, Humans, Longitudinal Studies, Male, Middle Aged, Patient Dropouts, Phobic Disorders, Placebos, Psychiatric Status Rating Scales, Citalopram, Survival Analysis, Treatment Outcome, Selective Serotonin Reuptake Inhibitors, Secondary Prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A 24-Week Randomized, Double-Blind, Placebo-Controlled Study of Escitalopram for the Prevention of Generalized Social Anxiety Disorder. https://app.cochat.ai/papers/10.4088/jcp.v66n1009
The paper
Montgomery, S. A., Nil, R., Dürr-Pal, N., Loft, H., & Boulenger, J.-P. (2005). A 24-Week Randomized, Double-Blind, Placebo-Controlled Study of Escitalopram for the Prevention of Generalized Social Anxiety Disorder. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.v66n1009

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.